AG-024322

AG-024322 is a potent ATP-competitive pan-CDK inhibitor against cell cycle kinases CDK1, CDK2, and CDK4 with Ki values in the 1-3 nM range[1]. AG-024322 displays broad-spectrum anti-tumor activity and clear target modulation in vivo. AG-024322 induces cell apoptosis[3].

Product Specifications

CAS Number

[837364-57-5]

UNSPSC

12352005

Target

Apoptosis; COX

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ag-024322.html

Purity

98.53

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=C(CNCC)C=NC=C1C2=CC3=C(NN=C3C4=NC5=CC(F)=CC(F)=C5N4)C=C2

Molecular Formula

C23H20F2N6

Molecular Weight

418.44

References & Citations

[1]Brown AP, et al. Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion.Cancer Chemother Pharmacol. 2008 Nov;62 (6) :1091-101.|[2]Jessen BA, et al. Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors.J Appl Toxicol. 2007 Mar-Apr;27 (2) :133-42.|[3]Cathy C. Zhang, et al. AG-024322 is a multi-targeted CDK inhibitor with potent antitumor activity in vivo. Cellular and Molecular Biology 53: Cell Cycle Control and Cancer 1